Published in J Immunother on April 01, 2011
Overview of current immunotherapeutic strategies for glioma. Immunotherapy (2015) 0.89
Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. PLoS One (2015) 0.83
Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation. Oncoimmunology (2012) 0.80
Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Protein Cell (2014) 0.80
Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics (2016) 0.79
Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells. PLoS One (2012) 0.79
Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines (2015) 0.75
Adenosine receptors as therapeutic targets. Nat Rev Drug Discov (2006) 6.15
Intracellular cytokine optimization and standard operating procedure. Nat Protoc (2006) 2.96
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol (2006) 1.79
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist (2008) 1.47
IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J Immunol (2003) 1.23
In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother (2007) 1.18
Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol (2009) 1.17
Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol (2009) 1.12
The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem (2007) 1.09
Imiquimod as an antiangiogenic agent. J Drugs Dermatol (2005) 1.03
Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. Cancer Gene Ther (2007) 1.03
Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol (2003) 0.99
Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res (2008) 0.98
More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. Int J STD AIDS (2010) 0.91
Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res (2004) 0.89
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res (2011) 2.06
Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev (2008) 1.65
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57
De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res (2009) 1.49
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med (2011) 1.42
Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.30
Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res (2010) 1.28
Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J Neurooncol (2006) 1.27
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos (2012) 1.19
In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother (2007) 1.18
GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res (2013) 1.16
Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol (2013) 1.02
Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol (2007) 0.99
Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clin Cancer Res (2010) 0.98
Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res (2008) 0.98
Efficacy of nonviral gene transfer in the canine brain. J Neurosurg (2007) 0.95
Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother (2013) 0.94
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther (2012) 0.94
Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Mol Ther (2013) 0.93
Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol Cancer Ther (2011) 0.91
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol (2010) 0.91
Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain. J Neurosurg (2011) 0.90
CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release (2013) 0.89
Identification of a novel monoclonal antibody recognizing CD133. J Immunol Methods (2010) 0.89
Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett (2012) 0.89
Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine (2010) 0.88
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin Cancer Res (2012) 0.87
Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol (2009) 0.85
CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma. J Immunol (2013) 0.85
Oxygen is a master regulator of the immunogenicity of primary human glioma cells. Cancer Res (2011) 0.85
Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer. PLoS One (2012) 0.84
Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS One (2010) 0.84
Adenoviral-mediated gene transfer into the canine brain in vivo. Neurosurgery (2007) 0.82
Identification and characterization of a novel scFv recognizing human and mouse CD133. Drug Deliv Transl Res (2013) 0.81
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction. ACS Med Chem Lett (2012) 0.79
Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Res (2013) 0.79
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction. J Med Chem (2014) 0.78
Emerging concepts in glioma biology: implications for clinical protocols and rational treatment strategies. Neurosurg Focus (2005) 0.78
9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. Cancer Chemother Pharmacol (2012) 0.77
MMuFLR: missense mutation and frameshift location reporter. Bioinformatics (2013) 0.77
Biphasic Dependence of Glioma Survival and Cell Migration on CD44 Expression Level. Cell Rep (2017) 0.75